BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15088144)

  • 1. Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients.
    Sauer CG; Kappeler A; Späth M; Kaden JJ; Michel MS; Mayer D; Bleyl U; Grobholz R
    Virchows Arch; 2004 Jun; 444(6):518-26. PubMed ID: 15088144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia.
    Upadhyay J; Shekarriz B; Nemeth JA; Dong Z; Cummings GD; Fridman R; Sakr W; Grignon DJ; Cher ML
    Clin Cancer Res; 1999 Dec; 5(12):4105-10. PubMed ID: 10632347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer.
    De Cicco C; Ravasi L; Zorzino L; Sandri MT; Botteri E; Verweij F; Granchi D; de Cobelli O; Paganelli G
    Curr Cancer Drug Targets; 2008 May; 8(3):199-206. PubMed ID: 18473733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
    Morgia G; Falsaperla M; Malaponte G; Madonia M; Indelicato M; Travali S; Mazzarino MC
    Urol Res; 2005 Feb; 33(1):44-50. PubMed ID: 15517230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
    Cardillo MR; Di Silverio F; Gentile V
    Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers.
    Kuniyasu H; Troncoso P; Johnston D; Bucana CD; Tahara E; Fidler IJ; Pettaway CA
    Clin Cancer Res; 2000 Jun; 6(6):2295-308. PubMed ID: 10873080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer.
    Kanoh Y; Akahoshi T; Ohara T; Ohtani N; Mashiko T; Ohtani S; Egawa S; Baba S
    Anticancer Res; 2002; 22(3):1813-7. PubMed ID: 12168874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
    Kuvaja P; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
    Hum Pathol; 2006 Oct; 37(10):1316-23. PubMed ID: 16949931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
    Szarvas T; Becker M; Vom Dorp F; Meschede J; Scherag A; Bánkfalvi A; Reis H; Schmid KW; Romics I; Rübben H; Ergün S
    Int J Cancer; 2011 Mar; 128(6):1486-92. PubMed ID: 20473942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies.
    Dreher T; Zentgraf H; Abel U; Kappeler A; Michel MS; Bleyl U; Grobholz R
    Virchows Arch; 2004 Jun; 444(6):509-17. PubMed ID: 15118854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of matrix metalloproteinase type IV-collagenases in serum of patients with tumors of the central nervous system.
    Ricci S; Guadagno E; Bruzzese D; Del Basso De Caro M; Peca C; Sgulò FG; Maiuri F; Di Carlo A
    J Neurooncol; 2017 Jan; 131(2):223-232. PubMed ID: 27757720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy.
    Kuniyasu H; Ukai R; Johnston D; Troncoso P; Fidler IJ; Pettaway CA
    Clin Cancer Res; 2003 Jun; 9(6):2185-94. PubMed ID: 12796385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Needle biopsy findings in prostatic adenocarcinoma: experience at a tertiary care center in a developing country.
    Ahmad Z; Arshad H
    Ann Diagn Pathol; 2013 Jun; 17(3):235-8. PubMed ID: 23199761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
    Brehmer B; Biesterfeld S; Jakse G
    Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of serum MMPs in tumor-bearing hamsters.
    Iki K; Takeo T; Kubozoe T; Aoki S; Hayashi J; Tsunoda T
    J Hepatobiliary Pancreat Surg; 2002; 9(4):478-84. PubMed ID: 12483270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunocytochemical detection of matrix metalloproteinase expression in prostate cancer.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    In Vivo; 2001; 15(1):65-70. PubMed ID: 11286132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression.
    Castellano G; Malaponte G; Mazzarino MC; Figini M; Marchese F; Gangemi P; Travali S; Stivala F; Canevari S; Libra M
    Clin Cancer Res; 2008 Nov; 14(22):7470-80. PubMed ID: 19010864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.